The Journal
Plain-language briefings on the science, with every claim cited. Updated as the literature moves.
Pipeline watchPP405: the follicle-reactivation drug everyone's watching
A factual, sourced briefing on the most-discussed name in the hair-loss pipeline — the mechanism, the Phase 2a data, and the honest gaps.
Evergreen — updated continuouslyThe state of the field
A living map of hair-loss research: what's approved, what's in study, and how to read pipeline news without getting played.
FundamentalsThe Norwood scale, honestly
The 7-stage classification clinicians actually use, why stage changes what the evidence says, and how to self-assess without fooling yourself.
Treatment landscapeFinasteride: what the trials actually showed
The pivotal evidence, the realistic effect size, and an honest accounting of the side-effect debate.
Treatment landscapeMinoxidil, reviewed
5% vs 2%, what "works" means in the data, and why consistency is the entire game.
Consumer skepticismThe supplement aisle audit
Saw palmetto, biotin, and proprietary blends — what the published record supports, and what it doesn't.